Crestor Use In Pregnancy & Lactation

Pregnancy: Rosuvastatin (CRESTOR) is not recommended for use in pregnant women. Rosuvastatin (CRESTOR) should be discontinued as soon as pregnancy is recognized. However, the ongoing therapeutic need and the individual benefit risk in patients with very high risk of cardiovascular events should be considered.
Published data from use of statins in pregnant women have not identified a drug-associated risk of major congenital malformations. However, due to Rosuvastatin (CRESTOR)'s mechanism of action, there is a potential risk for adverse reactions in the foetus. The data is insufficient to assess the risk of miscarriage.
Lactation: Breastfeeding is not recommended during treatment with Rosuvastatin (CRESTOR). Limited data from published reports indicate that Rosuvastatin (CRESTOR) is present in human milk. Due to Rosuvastatin (CRESTOR)'s mechanism of action, there is a potential risk for adverse reactions in the infant. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production.